Oncology Supplemental - FOI Response Register

FoI Number
2024-216
Subject
Oncology Supplemental
Date Received
15/07/2024
Request and Response
  1. Do you treat patients for Urothelial cancer (Yes or No)? If No, where do you refer patients for treatment

No, patients are treated at NHS Grampian

  1. How many patients were treated for Urothelial cancer (any stage) in the past 3 months with the following treatments:

•           Atezolizumab (Tecentriq)

•           Avelumab (Bavencio)

•           Carboplatin single agent or in any other combination

•           Carboplatin with Gemcitabine

•           Carboplatin with Paclitaxel

•           Cisplatin single agent or in any other combination

•           Cisplatin with Gemcitabine

•           Cisplatin with Gemcitabine + Nivolumab (Opdivo)

•           Enfortumab Vedotin + Pembrolizumab (Padcev + Keytruda)

•           Nivolumab (Opdivo)

•           Pembrolizumab (Keytruda)

•           Other active systemic anti-cancer therapy

•           Palliative care only

Zero

  1. Does your trust participate in any ongoing clinical trials for the treatment of urothelial cancer? If so, can you please provide the name of each trial along with the number of patients taking part?

Clinical trials are undertaken by NHS Grampian